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Cancer could be deemed as an abnormal and uncontrolled
tissue repair process. Therefore, it would not be surprising
that factors that function in the tissue repair process, such
as cytokines, chemokines, growth factors and Toll-like
receptor (TLR) ligands, as well as growth signals for
compensatory proliferation, would also be key factors in
regulating and enhancing cancer progression. The TLR
pathways, which play a critical role in tissue repair, are
also key regulators in cancer progression as well as
chemoresistance. TLRs serve as cell surface sensors that
can initiate pathways leading to proliferation and
chemoresistance; as well as mediators that are able to
regulate the inﬁltrating immune cells to provide further
support for cancer progression.
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Introduction
Inﬂammation is a relevant physiologic process necessary
for immune protection, tissue repair and tissue remodel-
ing. In tissue injury and the subsequent process of
wound healing, the inﬂammatory process mediated by
immune cells not only contains potential microorganism
invasion, but also promotes, in the surrounding tissue,
cell proliferation and neovascularization, which will
ensure appropriate healing and repair of the wound.
Similar process occurs in many organs of the body with
high cellular turnover rates such as the gastrointestinal
and reproductive tracts (Girling and Hedger, 2007).
In these tissues, the immune inﬁltrate and resulting
inﬂammatory process secure the removal of dying cells
and promotes the renewal of the tissue by enhancing cell
proliferation and maintaining adequate blood supply
(Mor et al., 2002). All these processes are mediated by
the production of cytokines and chemokines, which
function as the main regulators not only of immune
cells, but the entire cellular component of the speciﬁc
microenvironment (Lin and Karin, 2007).
In normal conditions, the inﬂammatory process is
tightly controlled, to secure that cell proliferation only
occurs until repair is completed or infection resolved. In
contrast, a chronic inﬂammatory process represents a
rich environment containing inﬂammatory cells and
growth/survival factors that could enhance the growth
of surrounding cells with already sustained DNA damage
or mutations, which may lead to the formation of a
tumor (Lin and Karin, 2007). Indeed, if we look at the
tumor microenvironment, it contains signiﬁcant amount
of immune inﬁltrates and has all the characteristics of an
ongoing inﬂammatory process (Chen et al., 2007c).
At present time, the relationship between inﬂammation
and tumorigenesis is widely accepted; however, the
cellular and molecular mechanism involved in this
process is incompletely understood. Our studies suggest
that cancer cells have acquired many properties char-
acteristic of immune cells, allowing them to communicate
and more importantly, regulate the immune system for
its own survival and growth (Kelly et al., 2006; Chen
et al., 2007b). The Toll-like receptors (TLRs), and their
intracellular signaling components, constitute an impor-
tant cellular pathway mediating this interaction and are
associated not only with the inﬂammatory process but
also with the development of chemoresistance. In this
review we will discuss the role of TLRs in tumor cells and
their role in the promotion of a proinﬂammatory/
progrowth microenvironment and the acquisition of
chemoresistance.
Inﬂammation and cancer
Numerous studies have provided convincing evidence
supporting the notion that bacterial- and viral-induced
inﬂammatory process can mediate tumorigenesis (Coussens
and Werb, 2002). Surgical removal of a primary tumor is
often followed by rapid growth of previously dormant
metastases as observed in in vivo studies and lipopolysac-
charide (LPS) has been suggested to be responsible for this
effect (Pidgeon et al., 1999). Indeed, Balb/c mice receiving a
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tail vein injection of 4T1 mouse mammary carcinoma cells
showed an increase in lung metastases following LPS
injection (Harmey et al., 2002). In humans, chronic infec-
tion and inﬂammation are considered two of the most
important epigenetic and environmental factors contri-
buting to tumorigenesis and tumor progression (Balkwill
and Coussens, 2004; Beachy et al., 2004).
In 1858, Rudolf Virchow noticed that the generation
of cancer often happened at sites of chronic inﬂamma-
tion (Virchow, 1858, 1863). He also hypothesized that
chronic inﬂammation could promote the proliferation of
cells and thus, the development of cancer. In the past 15
years, numerous cancers have been shown to be
associated with local chronic inﬂammation. Chronic
inﬂammatory bowel diseases such as chronic ulcerative
colitis and Crohn’s disease have strong association with
colon cancer (Balkwill and Coussens, 2004). Similarly,
gastric cancer has a strong link with chronicHelicobacter
pylori infection and the resulting inﬂammation (Ernst
et al., 2001). Ovarian endometriosis is an established risk
factor for certain types of epithelial ovarian cancers
(Giudice and Kao, 2004; Riman et al., 2004; Sekizawa
et al., 2004). Other examples include chronic bronchitis
and lung cancer, schistosomiasis and bladder cancer,
papillomavirus infection and cervical cancer, chronic
pancreatitis and pancreatic cancer, chronic cholecystitis
and gall bladder cancer, and hepatitis virus B and C
infection and liver cancer (Balkwill and Mantovani,
2001; Coussens and Werb, 2002; Li et al., 2005).
Moreover, epidemiological studies showed that regular
intake of nonsteroidal antiinﬂammatory drugs lowered
the risk of developing some types of cancers (Gupta and
Dubois, 2001; Balkwill and Coussens, 2004).
Toll-like receptor signaling pathways and their expression
in cancer cells
TLRs play a key role in the innate immune system,
particularly in inﬂammatory response against various
invading exogenous pathogens, by recognizing receptor-
speciﬁc pathogen-associated molecular patterns of
highly conserved pathogenic components of bacteria,
viruses, fungi and parasites (Takeda et al., 2003; Heil
et al., 2004; Takeda and Akira, 2004; Zhang et al., 2004;
Gorden et al., 2005; Yarovinsky et al., 2005). In
addition, TLRs can also be activated by endogenous
ligands, as shown in Table 1 (Leadbetter et al., 2002;
Heil et al., 2004; Tsan, 2006). Most TLRs signal through
a common pathway—the myeloid differentiation pri-
mary response gene 88 (MyD88)-dependent pathway
(Figure 1), since they possess a common intracellular
domain known as the Toll/interleukin (IL)-1 receptor
(TIR) domain (Rock et al., 1998). Following TLR
ligation, it recruits the adapter protein MyD88, which
associates with the intracellular domain of the receptor
through a TIR–TIR interaction (Muzio et al., 1997;
Wesche et al., 1997; Burns et al., 1998; Sato et al., 2003)
leading to subsequent downstream activation of the
nuclear factor of kappa light polypeptide gene enhancer
in B-cells (NF-kB) (early phase NF-kB activation) and
mitogen-associated protein (MAP) kinase signaling
pathways (such as the ERK-CREB pathway, the JNK-
AP1 pathway, and the p38 pathways). This signaling
cascade is responsible for the induction of a proin-
ﬂammatory response characterized by the production of
cytokines and chemokines, as well as cell proliferation
(McDermott and O’Neill, 2002).
Some TLRs (TLR3 and -4) can also induce NF-kB
activation via a MyD88-independent manner through
another TIR domain-containing adaptor molecule, the
TIR domain-containing adaptor inducing IFN-b
(TRIF) (Akira et al., 2003; Barton and Medzhitov,
2004; Takeda and Akira, 2004). The recruitment of
different signaling molecules by TRIF upon TLR
stimulation can lead to the activation of different
downstream mediators and targets (Figure 1). The
recruitment of TRAF6 to TRIF can activate NF-kB
via a MyD88-dependent pathway-like manner (late
phase NF-kB activation). The association of receptor-
interacting protein 1 with TRIF also activates NF-kB
through a yet unknown pathway (late phase NF-kB
activation).
Most of the reports on TLRs have focused on their
expression and function in cells of the immune system.
Recently however, TLR expression and function in
cancer cells and its association with tumorigenesis and
tumor progression has become a very active ﬁeld (Chen
et al., 2007c). In a recent study, Huang et al. (2005)
reported the expression of Tlr4 in murine tumor cell
lines and showed that the activation of Tlr4 in these
tumor cells by LPS-induced tumor evasion from
immune surveillance. Recently, our group described
the ubiquitous expression of TLR4 in human epithelial
ovarian cancer (EOC) cells and showed that in a
subgroup of EOC cells that express MyD88 (referred
from now on as type I EOC cells), ligation of TLR4 by
LPS-induced cell proliferation and enhanced cytokine/
chemokine production. This response was however, not
observed in the subgroup of EOC cells that do not
express MyD88 (referred from now on as type II EOC
cells) (Kelly et al., 2006).
Another recent study by Huang et al. (2007) showed
that Listeria monocytogenes (Lm) promotes tumor
growth through TLR2. Using an in vivo model, the
authors found that vaccination against Lm inhibited the
growth of H22 tumor cells while injection of Lm
enhanced cell growth. They showed that this effect was
mediated by direct interaction of the cancer cells with
the bacteria, as demonstrated by increased NF-kB
activity in cancer cells only in the animals expressing
Tlr2 but not in the Tlr2 knockout mice, following
injection of heat-killed Lm.
Similarly, He et al. (2007) described the expression of
TLR4 in human lung cancer cells. TLR4 ligation on the
cancer cells promoted the secretion of immunosuppres-
sive cytokines and induced resistance to TNFa and
TRAIL-induced apoptosis.
From these studies, it is reasonable to conclude that
the activation of TLRs in cancer cells and the ensuing
cytokine/chemokine production may have two major
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consequences: (1) the direct promotion of cancer cell
survival, chemoresistance and therefore tumor progres-
sion; and (2) the regulation of immune response within
the tumor microenvironment. Below, we will discuss
each of these potential effects.
TLRs promote tumor progression and chemoresistance
Inﬂammation-induced chemoresistance has been linked to
the hyperactivation of NF-kB in cancer cells (reviewed in
Nakanishi and Toi, 2005). The transcription factor NF-kB
upregulates the expression of many proinﬂammatory
cytokines, chemokines, growth factors, matrix metallo-
proteinases, adhesion molecules, and more importantly,
antiapoptotic proteins (Shishodia and Aggarwal, 2002;
Pikarsky et al., 2004).
It is well established that apoptosis or programmed
cell death is the key mechanism of most antitumor
therapies including chemotherapy, radiotherapy and
immunotherapy (Alvero et al., 2006). Activation of
NF-kB has been shown to induce upregulation of
antiapoptotic proteins such as c-FLIP and XIAP, and
to inhibit proapoptotic proteins such as Bax and
Caspase-9 (Kreuz et al., 2004). Taken together, these
cellular events may lead to chemo-resistance (Kamsteeg
et al., 2003; Pommier et al., 2004).
Central questions in these observations have been to
determine the factors inducing NF-kB activity in the
cancer cells. TNFa, which has been postulated as a
potential candidate, is a major inducer of NF-kB activity
promoting the early phase of activation (Covert et al.,
2005; Werner et al., 2005). Moreover, the activation of
TLRs in cancer cells may represent another important
pathway contributing to NF-kB activation. In ovarian
cancer cells with a functional TLR-MyD88 pathway (type
I EOC cells), treatment with ligands for TLR4 such as LPS
or paclitaxel increased the expression of XIAP and
phospho-AKT, two important regulators of cell survival
(Kelly et al., 2006). Similarly, the ligation of TLR2 in lung
cancer cells induced the activation of mitogen-activated
protein kinases (MAPK) as well as NF-kB, which were
shown to prolong cancer cell survival (Huang et al., 2007).
Cancer development shares many similarities with the
tissue repair process. First, both processes are triggered
by local tissue injury, and second, they are both aided
with the activity of the innate immune system, by way of
local inﬂammation (Coussens and Werb, 2002).
In both processes there is an increase in the stimulation
of cell proliferation. Contrary to the normal tissue repair
process, where cell proliferation is under strict control
and the process ends when the wound is completely
healed; in cancer, however, this process is out of control
and as a result—tumor progression ensues.
Therefore, it is plausible that cancer development is
an abnormal form of tissue repair, in which the control
mechanism loses its function by either mutation or being
aborted by abnormal proremodeling signals (such as
proinﬂammatory cytokines and growth factors).
An important stimuli for TLRs and subsequent effect
on cell proliferation and survival are molecules released
Figure 1 Toll-like receptor (TLR) signaling pathways. Membranal TLRs (represented by TLR4) recognize external ligands
(exogenous and endogenous), while cytoplasmic TLRs (TLR3) recognize intracellular signals. When activated, the majority of TLRs
induce activation of NF-kB (early phase NF-kB activation) and cytokine production in a MyD88-dependent manner; while TLR4, like
TLR3, can also signal in a MyD88-independent manner and induce the expression of type I interferons (IFN) and IFN-inducible
proteins in addition to a late phase NF-kB activation.
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during the process of tissue repair. The tissue repair
process has been reported to depend on TLR4-MyD88
signaling (Fukata et al., 2005). LPS was shown to
accelerate wound repair in vitro (Koff et al., 2006).
TLR4-MyD88 signaling is important to maintain
intestinal epithelial homeostasis in response to gut
injury, and both TLR4 and MyD88 knockout mice
displayed impaired compensatory proliferation and
increased apoptosis (Rakoff-Nahoum et al., 2004;
Fukata et al., 2005; Pull et al., 2005). Similarly, in a
mouse model of acute lung injury, hyaluronan released
from injured cells protected epithelial cells from
apoptosis through the TLR2/4-MyD88-NF-kB pathway
(Jiang et al., 2005).
Dying cells stimulate inﬂammation through TLRs and
MyD88 present in the immune cells, inducing a process
known as ‘sterile inﬂammatory response’ (Chen et al.,
2007a). The expression of TLRs by cancer cells may
facilitate a similar type of response to the presence of
dying cells, resulting from either normal tissue turnover
or in response to chemotherapy. Indeed, certain mole-
cules released by necrotic or apoptotic cells have been
described to be ligands for TLRs (Chen et al., 2007c).
Therefore, in the context where tumor cells have a
functional TLR-MyD88 pathway, as previously des-
cribed for epithelial ovarian cancer cells, the presence of
these molecules may initiate a signal leading to NF-kB
activation, and therefore promotion of an antiapoptotic
and progrowth microenvironment. There are multiple
evidence demonstrating that use of continuous cycles of
several chemotherapeutic drugs can induce initial tumor
reduction (cell death of the sensitive cells), which,
however, is followed immediately by recurrence of the
tumor characterized by a more aggressive phenotype. We
could argue that the partial induction of cell death in the
tumor can trigger a sterile inﬂammatory response
mediated by TLRs, present on cancer cells that survived
therapy. This would then initiate a process of ‘tissue
repair’, which in the context of neoplasia, involves tumor
growth. As we will discuss below, this seems to be the
case in chemoresistant ovarian cancer tumors.
TLRs, cancer cells and the tumor immune inﬁltrate
Immune inﬁltration is a remarkable phenomenon in
tumor development. The inﬁltrating host leukocytes,
such as neutrophils, tumor-associated macrophages
(TAMs), dendritic cells, eosinophils, mast cells and
lymphocytes, are present in both the supporting stroma
and the tumor sites, forming the inﬂammatory micro-
environment (Ben-Hur et al., 2000a, b; Balkwill and
Mantovani, 2001; Coussens and Werb, 2002). Pre-
viously, the immune inﬁltrates were thought to help the
host against the developing tumor, however, recent
studies showed that instead of combating the tumor,
the inﬁltrating immune cells contribute to cancer growth
and metastasis, as well as immunosuppression (Balkwill
and Mantovani, 2001; Coussens and Werb, 2002; Philip
et al., 2004). By analysing 1919 cases, Menard et al.
(1997) found that immune inﬁltration had no association
with survival and prognosis of breast carcinoma patients
more than 40 years of age. Furthermore, in previous
studies we found that the inﬁltrating macrophages in
breast carcinoma were a main source of estrogen, which
is a major stimulus for cell proliferation and cancer
progression (Mor et al., 1998). Similarly, Pollard
reported that the inﬁltration of macrophages stimulated
breast cancer progression and metastasis (Pollard, 2004),
and knocking out colony-stimulating factor-1 (CSF-1, a
cytokine that regulates macrophage differentiation and
function) in a mouse strain inhibited breast cancer
growth and metastasis. A study on oral epithelial
squamous cell carcinoma also revealed that the level of
immune cell inﬁltration was positively correlated with
the level of morphological and pathological transforma-
tion from normal to malignant phenotypes (Gannot
et al., 2002).
In ovarian cancer samples, staining for CD45, a
marker for leukocytes, revealed intensive immune
inﬁltration surrounding cancer cells and stroma
(Figure 2a) (Silasi et al., 2006). Interestingly, necrotic
centers represent as origins of the immune inﬁltrates and
from these centers the cells migrate towards the rest of
the tumor (Figure 2b). The presence of necrotic cells has
been proposed to represent one of the stimuli for
macrophage migration and differentiation (Lotze and
Tracey, 2005). Indeed, contrary to what would be
expected, the presence of necrosis in the tumor is
associated with bad prognosis. Many of the cellular
factors released by the dying cells may function as potent
stimuli to the immune cells, primarily macrophages
(Lotze and Tracey, 2005).
Therefore, as discussed above, the inﬂammatory
process is not only triggered by infection but also by
dying cells, and as in infection, the products of dying cells
need to be recognized by immune cells, or tumor cells, in
order to elicit the inﬂammatory response. During both
cancer development and tissue repair process, the
immune inﬁltrate is characterized by the presence of a
high number of macrophages. Further characterization
of these cells had led to the conclusion of the existence of
two subclasses of macrophages (M1 and M2 types of
macrophages) based on their cytokine proﬁle. M2
macrophages are the dominant subtype recognized
Figure 2 Immune inﬁltration in ovarian cancer samples.
(a) CD45-positive cells (brown) inﬁltrate between cancer cells
(blue) observed on a frozen section of primary ovarian cancer
tumor. (b) Necrotic centers may serve as potential origins of the
immune inﬁltrates and the cells may migrate into the rest of the
tumor from these centers.
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during tissue repair and in the protumor inﬂammatory
microenvironment. M2 macrophages promote tissue
repair and remodeling and are present in established
tumors and may promote tumor growth (Lewis and
Pollard, 2006). Unlike M1 macrophages, which are
known to mediate response against intracellular parasites
and tumors by producing IL-12, IL-23, IFNg, IL-18 and
TNFa, M2 macrophages have high levels of scavenger,
mannose and galactose-type receptors, produce VEGF,
IL-6, IL-10, PG, iNOS and IDO, and have immuno-
regulatory and proliferation-stimulating functions.
What directs macrophage differentiation at the tumor
microenvironment towards the M2 type or tumor-
supportive phenotype? A potential explanation is the
cancer cells themselves. We proposed three stages (Chen
et al., 2007c): (1) Recruitment: via the production of
chemokines (MCP-1, GROa and IL-8) cancer cells
recruit immune cells to the tumor microenvironment; (2)
Education: via the secretion of cytokines that regulate
immune cell differentiation (IL-6, TNFa and MIF)
tumor cells polarize immune cells towards tumor-
supporting cells and (3) Response: the differentiated
immune cells produce cytokines, hormones and growth
factors at the tumor microenvironment that promote
tumor growth and create immune tolerance (Figure 3).
For all these three stages, the expression of TLRs by
the cancer cells is a major factor. Through TLR2 or
TLR4, cancer cells can recognize either microbial
pathogens or cellular debris, and promote the expression
and secretion of chemokines and cytokines (for example,
MCP-1 and IL-8) which would work as mediators for
the regulation of immune cell migration, differentiation
and function (Figure 3).
The TLR4-MyD88-NF-jB pathway in ovarian cancer
Epithelial ovarian cancer is the most common form of
ovarian cancer and all patients with this diagnosis are
treated with the same regimen that includes the
combination of paclitaxel and carboplatin (Schwartz,
2002). However, the clinical response is not the same,
suggesting that there are additional differences that are
not associated with the histologic characteristics.
Our initial analysis for the expression of TLR4 in
ovarian cancer revealed a ubiquitous expression of this
receptor in those tumors; however, the response to
TLR4 ligation was not the same. Further analysis of the
intracellular components led us to the identiﬁcation of
type I and type II EOC cells based on their TLR4/TNFa
response which is associated with characteristics of
tumor adaptation and malignancy (Chen et al., 2007b).
Type I cells are characterized by the following: (i) a
functional TLR4 signaling pathway; (ii) constitutive
cyclic activity of NF-kB; (iii) continuous production of
cytokines, which is further enhanced by TLR4 ligation
(with either LPS or paclitaxel) and TNFa stimulation;
(iv) high expression of MyD88, low IkBa and a high
IKKb/IKKa ratio; and (v) chemoresistance. Type II
cells, however, do not have a functional TLR-MyD88
pathway and do not constitutively produce cytokines,
and are chemosensitive.
Interestingly, the functional TLR-MyD88 pathway in
type I cells contributes to the maintenance of the
proinﬂammatory microenvironment by secreting a
substantially elevated level of cytokines and chemo-
kines, all of which lead to further tumor growth. The
characteristic proinﬂammatory environment generated
by type I EOC cells was lost upon the knockdown of
MyD88, suggesting that an active MyD88-dependent
TLR4 signaling is responsible for the LPS-induced, NF-
kB-mediated EOC cell proliferation and cytokine
secretion (Kelly et al., 2006). In contrast, type II EOC
cells do not constitutively secrete cytokines, and no
changes in cell proliferation or cytokine production were
observed following LPS treatment.
Type I EOC cells also use TLRs to communicate with
and ‘educate’ the immune cells. Indeed, we observed
that the upregulated chemokine expression in type I
EOC cells upon TLR4 stimulation by LPS-induced
in vitro monocyte migration and differentiation into a
protumor phenotype (unpublished data).
Tumors are made of heterogeneous cell populations,
which is also evidenced in ovarian cancer tumors in term
of type I and II (Figure 4). The ratio of type I
(potentially cancer stem cells, highly resistant to
proapoptotic signals) versus type II (more differentiated
and sensitive to apoptotic signals) may determine the
growth of the tumor and the outcome in response to
therapy. The type I cells may serve as resources of
cytokines, chemokines and other signaling molecules
that promote tumor progression, neovascularization
and ‘education’ of the immune inﬁltrates; while the
turnover and/or chemotherapy-induced apoptosis of the
sensitive type II cells would further activate the tissue
repair potential of the inﬁltrated immune cells (M2
macrophages in particular) and lead to even elevated
tumor growth.
In summary, these ﬁndings suggest that the proinﬂam-
matory conditions observed at the tumor microenvironment
Figure 3 Tumor-immune cell ‘Education’ model. Cancer cells
secrete chemokines to recruit immune cells (Recruitment), induce
their differentiation into protumor cells (Education) and receive
support from the differentiated immune cells (Response). GROa,
growth-regulated protein alpha; IL-8, interleukin-8; MCP-1,
monocyte chemo-attractant protein-1; MIF, macrophage migra-
tion inhibitory factorTNFa, tumor necrosis factor-alpha.
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may not only originate from the immune cells, but also
from the cancer cells as well. However, this capacity is not
intrinsic to all the cancer cells, but to a selected population
which has acquired a functional TLR4-MyD88-NF-kB
signaling pathway. We hypothesize that it is the elevated
repair capacity of type I EOC cells after chemotherapeutic
drug treatment that results in the subsequent development
of chemoresistance and tumor recurrence. Finally, cancer
cells can ‘educate’ the immune inﬁltrates to produce the
type of cytokines that will facilitate tumor growth and
metastasis as well as acquiring immune tolerance (Figure 5).
Epigenetic regulation of TLR function—miRNAs, TLR
signaling and cancer
microRNAs (miRNAs) are a class of small RNA
molecules that regulate gene expression at post-tran-
scriptional level (Ruvkun, 2001; Rana, 2007). They
work by complementing sequence-speciﬁc targets in the
30-UTR of mRNAs through incorporation to RNA-
induced silencing complex (RISC), which leads to either
the degradation of the target mRNA (if the miRNA and
its target sequence is a perfect match), or the inhibition
of the target mRNA translation (if the match between
miRNA and its target sequence is imperfect) (Wiemer,
2007). Recent studies have demonstrated a link between
miRNAs and TLR function, and therefore potential
association with inﬂammation and cancer formation.
miR-155 is one of the most studied miRNAs related to
inﬂammation and cancer. It has been found highly
expressed in B-cell lymphoma, breast and lung cancers,
and pancreatic adenocarcinomas (Tam et al., 1997; Eis
et al., 2005; Calin and Croce, 2006; Esquela-Kerscher and
Slack, 2006; Wiemer, 2007). Recent works by various
groups gradually unveil the function of miR-155. O’Con-
nell et al. (2007) observed that ligands for TLR2, TLR3,
TLR4 and TLR9 could all induce the upregulation of
miR-155 expression, through both MyD88- and TRIF-
dependent pathways, and the expression of miR-155 is
JNK-dependent. Our group also found that miR-155 was
highly expressed in type I EOC cells, suggesting that miR-
155 may be necessary for maintaining a normal proin-
ﬂammatory protumor environment mediated by these cells
(Chen et al., 2007b).
miR-146 has been reported to be highly expressed in
breast, prostate, pancreatic, stomach and papillary
thyroid carcinomas (He et al., 2005; Volinia et al.,
2006; Wiemer, 2007). He et al. (2005) also found that the
high expression of miR-146 distinguished papillary
thyroid cancers from healthy controls. In ovarian cancer
cells, we observed high level of miR-146a expression in
type I but not type II EOC cells, indicating a role of
miR-146 in regulating the proinﬂammatory character-
istics of type I cells (Chen et al., 2007b). Indeed, both
miR-146a and miR-146b are targets of NF-kB, and are
upregulated upon TLR2, TLR4 or TLR5 ligation as
well as TNFa or IL-1b stimulation (Taganov et al.,
2006). Taganov et al. (2006) also identiﬁed IRAK1 and
TRAF6 as direct targets of miR-146, indicating that
miR-146 may be important negative regulators of the
TLR signaling pathway.
In addition, we recently reported the role of miR-199a
as regulator of IKKb expression in ovarian cancer cells
(Chen et al., 2007b). In this case the absence of miR-
199a expression in type I cells results in a high IKKb
expression level, which is associated with a functional
TLR/MyD88 pathway, cytokine production and more
important, chemoresistance. The case is vice versa in
type II cells. The loss of the inhibitory effect of miR-
199a on IKKb expression in type I cells may represent
an evolutionary ﬁne-tuning during the development of
chemoresistant cells. These ﬁndings suggest that miR-
NAs may provide invaluable targets to treat chemore-
sistant cancers.
Figure 4 Heterogeneity of epithelial ovarian cancer (EOC)
tumors. Type I and type II EOC cells could both be seen on a
frozen section of a representative primary EOC tumor. This
indicates that the ratio between type I and type II cells may
determine the characteristics of the tumor in terms of growth,
recurrence and chemoresistance. Figure 5 Inﬂammation—Toll-like receptor (TLR)- and tumor
immune interaction. TLR-mediated NF-kB activation induces
proinﬂammatory cytokine production, which could promote
cancer cell proliferation and induce immune cells differentiation
toward a tumor-supporting phenotype. Cytokines produced by the
tumor induce the differentiation of macrophages towards a M2
phenotype, prevents maturation of iDC and therefore maintaining
a tolerance stage increase the number of T reg cells with subsequent
inhibition of T cells. Yellow arrows, promotion; red arrows,
inhibition.
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Conclusion
Cancer could be deemed as an abnormal and uncon-
trolled tissue repair process. Therefore, it would not be
surprising that factors that function in the tissue repair
process, such as cytokines, chemokines, growth factors
and TLR ligands, as well as growth signals for
compensatory proliferation, would also be key factors
in regulating and enhancing cancer progression. The
TLR pathways, which play a critical role in tissue repair,
are also key regulators in cancer progression as well as
chemoresistance. On the one hand, they serve as cell
surface sensors that can initiate pathways leading to
proliferation and chemoresistance; on the other, they are
also mediators that are able to regulate the inﬁltrating
immune cells to provide further support for cancer
progression. Moreover, microRNAs that regulate at
different levels of the TLR pathways, may function as
either oncogenes or tumor suppressors and their
abnormal expression may further facilitate cancer
growth. Better understanding of the function and
regulation of the TLR signaling pathways in cancer
may shed new lights on understanding the mecha-
nisms of cancer formation and progression, as well as
provide new targets for more effective regimens to treat
cancer.
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